|
Agitation
study:
Data Sheet, Study Flow,
Data Collection Tips,
FAQs
|
|
Overview: This
study is designed to evaluate the effectiveness of three drugs,
droperidol (Inapsin), ziprasidone (Geodon), and lorazepam (Ativan)
in the treatment of acute undifferentiated agitation in patients
presenting to the emergency department.
|
|
Primary Endpoints: 1.
Respiratory depression as assessed by ETCO2 and pulse Ox 2. Mental
status as assessed AMSS and BARS.
|
|
Eligible Patients: The
patient must be over 18 and have been diagnosed with acute
undifferentiated agitation that requires
treatment who are not allergic to geodon, ativan, or droperidol.
|
|
Study Design: Prospective
randomized clinical trial
|
|
Anticipated Benefits:
Achieving adequate sedation
|
|
Potential Risks:
Inadequate sedation or adverse reactions to the
medicines.
|
|
Research Associate’s Role:
The RA will identify and enroll eligible patients. The RA will
need to obtain an AMSS, pulse oximetry, and end tidal CO2
scores at the specified times.
|
|
Physician’s Role: The
physician will be asked to help identify eligible patients and
informing the RAs to enroll the patients. Additionally, the
physician may be asked about complications the patient underwent in
the two-hour observation period.
|
|
Location of Study Packets:
Special Care
|
